UOC
NDRM

UBS O'Connor’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

UBS O'Connor’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-40,000
Closed -$682K – 580
2015
Q4 		$682K Buy
+40,000
New +$779K 0.01% 344

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

UBS O'Connor's NDRM Position: Q1 2016 in Review

UBS O'Connor sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q1 2016, closing a stake of 40,000 shares — an estimated $682K sold.

UBS O'Connor first reported a position in NDRM in Q4 2015 and held it in 1 quarter. The position peaked at $682K in Q4 2015. 50 funds tracked by Wall St. Rank hold NDRM as of Q1 2016.

  • UBS O'Connor reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • UBS O'Connor sold 40,000 NeuroDerm Ltd. Ordinary Shares shares in Q1 2016, an estimated $682K.
  • UBS O'Connor first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 1 quarter.
  • UBS O'Connor's NeuroDerm Ltd. Ordinary Shares position peaked at $682K in Q4 2015.
  • 50 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q1 2016.

Based on UBS O'Connor's 13F filing for Q1 2016, filed 13 May 2016.